Eikon Therapeutics

NASDAQ: EIKN

Buy

Buy Eikon Therapeutics shares

Sign up to view historical trading trends and place an offer.

Sell

Sell Eikon Therapeutics shares

Understand share pricing, list anonymously, and benefit from transparent fees.

Overview

Eikon Therapeutics completed their IPO on February 5, 2026. Now that Eikon Therapeutics is a public company, Nasdaq Private Market does not actively track its performance. The data below is for reference before the company’s IPO.

Eikon Therapeutics is a biotechnology company focused on pioneering new methods of drug discovery through advanced imaging techniques. Eikon aims to revolutionize the understanding of protein dynamics and their implications for therapeutic development.

Sector

Health Care

Founded

2019

Headquarters

Roseland, NJ

Eikon Therapeutics Funding

Eikon Therapeutics Funding History Pre-IPO

Gain insights into Eikon Therapeutics funding history prior to their IPO, including the funding round, time period, and amount raised.

Financing Round Date Amount Price per share Valuation
Round Date Amount PPS Valuation
Series B Feb 26, 2025 351M
XXXXX
XXXXX
Series C May 18, 2023 141M
XXXXX
XXXXX
Series B Dec 03, 2021 518M
XXXXX
XXXXX
Series A May 04, 2021 48M
XXXXX
XXXXX
Series A May 04, 2021 108M
XXXXX
XXXXX

Access the PPS, Valuation details, and a wealth of other data by signing up. Source: Nasdaq Private Market Tape D®

Buy

Buy Eikon Therapeutics shares

Sign up to view historical trading trends and place an offer.

Sell

Sell Eikon Therapeutics shares

Understand share pricing, list anonymously, and benefit from transparent fees.

Eikon Therapeutics Management Team

Eikon Therapeutics people and management – Prior to IPO

  • Board Member
    Dror Berman
  • Chief Information Officer
    Ashish Kheterpal
  • President, Board Member
    Leon Chen
  • Board Member
    James Tannanbaum
  • COO
    Mike Klobuchar
  • CTO
    Russ Berman
  • Board Member
    Josh Wolfe
  • Chief Scientific Officer
    Dan Anderson
  • Board Member
    Robin Washington
  • Co-Founder
    Xavier Darzacq
  • Co-Founder
    Robert Tjian
  • Chief Business Officer
    Benjamin Thorner
  • Chief People Officer
    Barbara Howes
  • CEO, Director
    Roger Perlmutter
  • Board Member
    Kenneth Frazier
  • Chief Medical Officer
    Roy Baynes
  • CFO
    Alfred Bowie
  • Co-Founder
    Eric Betzig

Investors

Major Eikon Therapeutics investors

  • Column Group

  • UC Investments (UCOP)

  • Horizon Ventures

  • E15 VC

  • AME Cloud Ventures

  • Hartford HealthCare Endowment

  • T. Rowe Price

  • Lux Capital

  • StepStone Group

  • Harel Insurance Investements & Financial Services

  • Foresite Capital

  • Innovation Endeavors

  • General Catalyst

  • Canada Pension Plan Investment Board (CPPIB)

  • Soros Fund Management

  • Abu Dhabi Investment Authority (ADIA)

  • EcoR1 Capital

  • Schroders Capital

Eikon Therapeutics Valuations & Financials

Gain insights Into Eikon Therapeutics Stock Valuation & Share Prices

View real-time NPM data on Eikon Therapeutics stock including most recent valuation and historical share price information. Are you an institutional investor or employee shareholder? Sign up to the SecondMarket trading platform.

Similar Companies

Explore companies

like Eikon Therapeutics

  • Cityblock Health-Logo

    Cityblock Health

    Health Care

    Tech-driven care provider for communities with complex needs.

  • Benchling-Logo

    Benchling

    Health Care

    Cloud based platform for research and development in biotechnology.

  • Insitro-Logo

    insitro

    Health Care

    Drug discovery and development company.

  • Lyra Healthcare-Logo

    Lyra

    Health Care

    Digital health startup using technology to connect companies and employees to mental health providers.

  • Tonal Strong-Logo

    Tonal

    Health Care

    Delivers AI-powered strength training with digital weights and personalized coaching.

  • Curology-Logo

    Curology

    Health Care

    Offers personalized prescription skin care medications delivered directly to you.

  • Arsenalbio-Logo

    ArsenalBio

    Health Care

    Develops programmable cell therapies for cancer patients.

  • Rakuten Medical-Logo

    Rakuten Medical

    Health Care

    Develops targeted cancer treatments using photoimmunotherapy technology to create more effective and accessible therapeutic solutions.

  • Tessera Therapeutics-Logo

    Tessera Therapeutics

    Health Care

    Genome engineering technology that writes therapeutic messages into the genome to treat diseases at their source.

FAQ

Questions?

We have answers

Buy Eikon Therapeutics Stock

Eikon Therapeutics became publicly traded following its IPO on February 5, 2026, its shares now trade on public stock exchanges under the ticker symbol NASDAQ: EIKN. Before the IPO, Eikon Therapeutics stock was privately held and available only through private market transactions.

If you’re an accredited investor looking to purchase pre-IPO shares in a private company, Nasdaq Private Market can help you get started. Learn more about investing in the private market or sign up for free to explore available opportunities. Learn more about how private company shares trade prior to an IPO on our investors page.

Sell Eikon Therapeutics Stock

Following its IPO on February 5, 2026, Eikon Therapeutics shares trade on public stock exchanges, allowing shareholders to sell stock through a traditional brokerage.

If you currently hold shares in a private company, Nasdaq Private Market may be able to help you explore your sell private company stock. Our platform provides a secure and compliant way to sell your shares on terms that work for both you and the company. To understand how employees sell shares before a company goes public, visit the Employee Shareholders page.

Eikon Therapeutics Stock Price

Following the IPO, Eikon Therapeutics stock prices can now be viewed publicly on major exchanges. Investors and interested parties can find the current stock price by searching Eikon Therapeutics’s ticker symbol on financial platforms such as Nasdaq.com or through their preferred brokerage platform.

Eikon Therapeutics Stock Ticker Symbol

Following its IPO on February 5, 2026, Eikon Therapeutics stock now trades on public markets under the ticker symbol NASDAQ: EIKN. You can view real-time stock information through widely used financial data platforms.

Criteria to Sell Eikon Therapeutics Stock

Following the Eikon Therapeutics IPO, public shares can be sold through any brokerage.

Nasdaq Private Market works with employees, ex-employees, and other private company shareholders of pre-IPO companies to sell their shares. The Nasdaq Private Market platform provides a secure and compliant way to sell your shares on terms that work for both you and the company. To learn more about how to sell private company stock, visit the Employee Shareholders page.

Read more about how to sell shares of a private company and eligibility for selling privately held stock:

Criteria to Buy or Invest in Eikon Therapeutics Stock

Following Eikon Therapeutics’s initial public offering on February 5, 2026, its shares are now listed on a public exchange and available for purchase through a brokerage account. Investors interested in buying Eikon Therapeutics stock can do so through their preferred broker, just as they would with any other publicly traded security.

Nasdaq Private Market continues to work with investors seeking exposure to private company opportunities prior to IPO. Through structured transactions and curated offerings, investors can participate in private market activity before companies enter the public markets.

Learn more about the Nasdaq Private Market tool kit for investors on the Investor Trading page.

Eikon Therapeutics Stock Settlement

Since Eikon Therapeutics is now publicly traded, public-market share transfers and settlement occur automatically through a brokerage or exchange.

Nasdaq Private Market supports transfer and settlement for privately held company equity. In order to buy or sell private company stock, share ownership must transfer before funds are wired. With Nasdaq Private Market, clients leverage our patented Transfer and Settlement technology which streamlines and manages transfer activity from match to settlement.

To learn more about private company stock Transfer and Settlement, check out the Transfer and Settlement page.

Eikon Therapeutics IPO

Eikon Therapeutics completed its IPO on February 5, 2026, and is now publicly available through major financial sources.